GASTROENTEROLOGY-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=527759, encodeId=6c2552e75953, content=被拒！编辑部，给了一个意见。一个月一篇类似文章和你类似！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=516, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Thu Sep 29 20:58:00 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=527733, encodeId=892752e73314, content=Under review 8天，现在decision in process, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=339, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Thu Sep 29 00:07:00 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=527692, encodeId=c13552e69216, content=也只能这样了，万一给拒了，希望给点意见。青龙偃月 2016-09-26 发表:: 耐心等结果吧, beContent=青龙偃月 2016-09-26 发表:: 耐心等结果吧, objectType=tool_impact_factor, channel=null, level=null, likeNumber=333, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Wed Sep 28 00:53:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=527636, encodeId=d8be52e63687, content=耐心等结果吧slientwo 2016-09-25 发表:: 接收率：约25% 审稿时间：约1个月 Meta分析，在投，under review，5天。会不会不送外审就被拒！, beContent=slientwo 2016-09-25 发表:: 接收率：约25% 审稿时间：约1个月 Meta分析，在投，under review，5天。会不会不送外审就被拒！, objectType=tool_impact_factor, channel=null, level=null, likeNumber=433, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160905/IMG57CD39B82D12E7926.jpg, createdBy=ac2c1946830, createdName=青龙偃月, createdTime=Mon Sep 26 22:09:00 CST 2016, time=2016-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=527588, encodeId=3ad452e588ca, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：Meta分析，在投，under review，5天。会不会不送外审就被拒！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=312, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Sep 25 17:21:00 CST 2016, time=2016-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=833102, encodeId=1df48331029e, content=老牌经典期刊，难度较大 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6e05414152, createdName=ms2614478266438915, createdTime=Wed Aug 17 13:31:54 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=524581, encodeId=fa9e52458108, content=是的rolly11 2016-02-29 发表:: 好像挺快的, beContent=rolly11 2016-02-29 发表:: 好像挺快的, objectType=tool_impact_factor, channel=null, level=null, likeNumber=377, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/25/ba882cb566d3be250a05e2a69b80f2c9.jpg, createdBy=32881678798, createdName=小M医师, createdTime=Thu Jul 07 15:13:00 CST 2016, time=2016-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519698, encodeId=ab9751969855, content=好像挺快的Atlantis 2016-02-10 发表:: 研究方向：淋巴瘤;; 接收率：约75% case report 2015.12.23投稿 2015.12.30改格式 2016.2.8接收, beContent=Atlantis 2016-02-10 发表:: 研究方向：淋巴瘤;; 接收率：约75% case report 2015.12.23投稿 2015.12.30改格式 2016.2.8接收, objectType=tool_impact_factor, channel=null, level=null, likeNumber=465, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=078f1661649, createdName=wei834766788, createdTime=Mon Feb 29 10:02:00 CST 2016, time=2016-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519643, encodeId=b94851964356, content=正常12112312312313 2016-02-02 发表:: 会的, beContent=12112312312313 2016-02-02 发表:: 会的, objectType=tool_impact_factor, channel=null, level=null, likeNumber=359, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=078f1661649, createdName=wei834766788, createdTime=Fri Feb 26 23:03:00 CST 2016, time=2016-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519645, encodeId=1929519645f8, content=看情况的吧zpfsjtu 2016-02-01 发表:: 研究方向：肝癌;泛素化; 这个杂志都是什么状态呀。昨天投稿，今天就under review。应该不会这么快吧。, beContent=zpfsjtu 2016-02-01 发表:: 研究方向：肝癌;泛素化; 这个杂志都是什么状态呀。昨天投稿，今天就under review。应该不会这么快吧。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=469, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=078f1661649, createdName=wei834766788, createdTime=Fri Feb 26 23:02:00 CST 2016, time=2016-02-26, status=1, ipAttribution=)]

2016-09-29 slientwo

被拒！编辑部，给了一个意见。一个月一篇类似文章和你类似！

516 0

[GetPortalCommentsPageByObjectIdResponse(id=527759, encodeId=6c2552e75953, content=被拒！编辑部，给了一个意见。一个月一篇类似文章和你类似！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=516, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Thu Sep 29 20:58:00 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=527733, encodeId=892752e73314, content=Under review 8天，现在decision in process, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=339, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Thu Sep 29 00:07:00 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=527692, encodeId=c13552e69216, content=也只能这样了，万一给拒了，希望给点意见。青龙偃月 2016-09-26 发表:: 耐心等结果吧, beContent=青龙偃月 2016-09-26 发表:: 耐心等结果吧, objectType=tool_impact_factor, channel=null, level=null, likeNumber=333, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Wed Sep 28 00:53:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=527636, encodeId=d8be52e63687, content=耐心等结果吧slientwo 2016-09-25 发表:: 接收率：约25% 审稿时间：约1个月 Meta分析，在投，under review，5天。会不会不送外审就被拒！, beContent=slientwo 2016-09-25 发表:: 接收率：约25% 审稿时间：约1个月 Meta分析，在投，under review，5天。会不会不送外审就被拒！, objectType=tool_impact_factor, channel=null, level=null, likeNumber=433, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160905/IMG57CD39B82D12E7926.jpg, createdBy=ac2c1946830, createdName=青龙偃月, createdTime=Mon Sep 26 22:09:00 CST 2016, time=2016-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=527588, encodeId=3ad452e588ca, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：Meta分析，在投，under review，5天。会不会不送外审就被拒！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=312, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Sep 25 17:21:00 CST 2016, time=2016-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=833102, encodeId=1df48331029e, content=老牌经典期刊，难度较大 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6e05414152, createdName=ms2614478266438915, createdTime=Wed Aug 17 13:31:54 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=524581, encodeId=fa9e52458108, content=是的rolly11 2016-02-29 发表:: 好像挺快的, beContent=rolly11 2016-02-29 发表:: 好像挺快的, objectType=tool_impact_factor, channel=null, level=null, likeNumber=377, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/25/ba882cb566d3be250a05e2a69b80f2c9.jpg, createdBy=32881678798, createdName=小M医师, createdTime=Thu Jul 07 15:13:00 CST 2016, time=2016-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519698, encodeId=ab9751969855, content=好像挺快的Atlantis 2016-02-10 发表:: 研究方向：淋巴瘤;; 接收率：约75% case report 2015.12.23投稿 2015.12.30改格式 2016.2.8接收, beContent=Atlantis 2016-02-10 发表:: 研究方向：淋巴瘤;; 接收率：约75% case report 2015.12.23投稿 2015.12.30改格式 2016.2.8接收, objectType=tool_impact_factor, channel=null, level=null, likeNumber=465, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=078f1661649, createdName=wei834766788, createdTime=Mon Feb 29 10:02:00 CST 2016, time=2016-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519643, encodeId=b94851964356, content=正常12112312312313 2016-02-02 发表:: 会的, beContent=12112312312313 2016-02-02 发表:: 会的, objectType=tool_impact_factor, channel=null, level=null, likeNumber=359, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=078f1661649, createdName=wei834766788, createdTime=Fri Feb 26 23:03:00 CST 2016, time=2016-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519645, encodeId=1929519645f8, content=看情况的吧zpfsjtu 2016-02-01 发表:: 研究方向：肝癌;泛素化; 这个杂志都是什么状态呀。昨天投稿，今天就under review。应该不会这么快吧。, beContent=zpfsjtu 2016-02-01 发表:: 研究方向：肝癌;泛素化; 这个杂志都是什么状态呀。昨天投稿，今天就under review。应该不会这么快吧。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=469, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=078f1661649, createdName=wei834766788, createdTime=Fri Feb 26 23:02:00 CST 2016, time=2016-02-26, status=1, ipAttribution=)]

2016-09-29 slientwo

Under review 8天，现在decision in process

339 0

[GetPortalCommentsPageByObjectIdResponse(id=527759, encodeId=6c2552e75953, content=被拒！编辑部，给了一个意见。一个月一篇类似文章和你类似！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=516, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Thu Sep 29 20:58:00 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=527733, encodeId=892752e73314, content=Under review 8天，现在decision in process, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=339, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Thu Sep 29 00:07:00 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=527692, encodeId=c13552e69216, content=也只能这样了，万一给拒了，希望给点意见。青龙偃月 2016-09-26 发表:: 耐心等结果吧, beContent=青龙偃月 2016-09-26 发表:: 耐心等结果吧, objectType=tool_impact_factor, channel=null, level=null, likeNumber=333, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Wed Sep 28 00:53:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=527636, encodeId=d8be52e63687, content=耐心等结果吧slientwo 2016-09-25 发表:: 接收率：约25% 审稿时间：约1个月 Meta分析，在投，under review，5天。会不会不送外审就被拒！, beContent=slientwo 2016-09-25 发表:: 接收率：约25% 审稿时间：约1个月 Meta分析，在投，under review，5天。会不会不送外审就被拒！, objectType=tool_impact_factor, channel=null, level=null, likeNumber=433, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160905/IMG57CD39B82D12E7926.jpg, createdBy=ac2c1946830, createdName=青龙偃月, createdTime=Mon Sep 26 22:09:00 CST 2016, time=2016-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=527588, encodeId=3ad452e588ca, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：Meta分析，在投，under review，5天。会不会不送外审就被拒！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=312, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Sep 25 17:21:00 CST 2016, time=2016-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=833102, encodeId=1df48331029e, content=老牌经典期刊，难度较大 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6e05414152, createdName=ms2614478266438915, createdTime=Wed Aug 17 13:31:54 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=524581, encodeId=fa9e52458108, content=是的rolly11 2016-02-29 发表:: 好像挺快的, beContent=rolly11 2016-02-29 发表:: 好像挺快的, objectType=tool_impact_factor, channel=null, level=null, likeNumber=377, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/25/ba882cb566d3be250a05e2a69b80f2c9.jpg, createdBy=32881678798, createdName=小M医师, createdTime=Thu Jul 07 15:13:00 CST 2016, time=2016-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519698, encodeId=ab9751969855, content=好像挺快的Atlantis 2016-02-10 发表:: 研究方向：淋巴瘤;; 接收率：约75% case report 2015.12.23投稿 2015.12.30改格式 2016.2.8接收, beContent=Atlantis 2016-02-10 发表:: 研究方向：淋巴瘤;; 接收率：约75% case report 2015.12.23投稿 2015.12.30改格式 2016.2.8接收, objectType=tool_impact_factor, channel=null, level=null, likeNumber=465, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=078f1661649, createdName=wei834766788, createdTime=Mon Feb 29 10:02:00 CST 2016, time=2016-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519643, encodeId=b94851964356, content=正常12112312312313 2016-02-02 发表:: 会的, beContent=12112312312313 2016-02-02 发表:: 会的, objectType=tool_impact_factor, channel=null, level=null, likeNumber=359, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=078f1661649, createdName=wei834766788, createdTime=Fri Feb 26 23:03:00 CST 2016, time=2016-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519645, encodeId=1929519645f8, content=看情况的吧zpfsjtu 2016-02-01 发表:: 研究方向：肝癌;泛素化; 这个杂志都是什么状态呀。昨天投稿，今天就under review。应该不会这么快吧。, beContent=zpfsjtu 2016-02-01 发表:: 研究方向：肝癌;泛素化; 这个杂志都是什么状态呀。昨天投稿，今天就under review。应该不会这么快吧。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=469, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=078f1661649, createdName=wei834766788, createdTime=Fri Feb 26 23:02:00 CST 2016, time=2016-02-26, status=1, ipAttribution=)]

2016-09-28 slientwo

也只能这样了，万一给拒了，希望给点意见。青龙偃月 2016-09-26 发表::
耐心等结果吧

青龙偃月 2016-09-26 发表:: 耐心等结果吧

333 0

[GetPortalCommentsPageByObjectIdResponse(id=527759, encodeId=6c2552e75953, content=被拒！编辑部，给了一个意见。一个月一篇类似文章和你类似！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=516, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Thu Sep 29 20:58:00 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=527733, encodeId=892752e73314, content=Under review 8天，现在decision in process, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=339, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Thu Sep 29 00:07:00 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=527692, encodeId=c13552e69216, content=也只能这样了，万一给拒了，希望给点意见。青龙偃月 2016-09-26 发表:: 耐心等结果吧, beContent=青龙偃月 2016-09-26 发表:: 耐心等结果吧, objectType=tool_impact_factor, channel=null, level=null, likeNumber=333, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Wed Sep 28 00:53:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=527636, encodeId=d8be52e63687, content=耐心等结果吧slientwo 2016-09-25 发表:: 接收率：约25% 审稿时间：约1个月 Meta分析，在投，under review，5天。会不会不送外审就被拒！, beContent=slientwo 2016-09-25 发表:: 接收率：约25% 审稿时间：约1个月 Meta分析，在投，under review，5天。会不会不送外审就被拒！, objectType=tool_impact_factor, channel=null, level=null, likeNumber=433, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160905/IMG57CD39B82D12E7926.jpg, createdBy=ac2c1946830, createdName=青龙偃月, createdTime=Mon Sep 26 22:09:00 CST 2016, time=2016-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=527588, encodeId=3ad452e588ca, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：Meta分析，在投，under review，5天。会不会不送外审就被拒！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=312, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Sep 25 17:21:00 CST 2016, time=2016-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=833102, encodeId=1df48331029e, content=老牌经典期刊，难度较大 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6e05414152, createdName=ms2614478266438915, createdTime=Wed Aug 17 13:31:54 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=524581, encodeId=fa9e52458108, content=是的rolly11 2016-02-29 发表:: 好像挺快的, beContent=rolly11 2016-02-29 发表:: 好像挺快的, objectType=tool_impact_factor, channel=null, level=null, likeNumber=377, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/25/ba882cb566d3be250a05e2a69b80f2c9.jpg, createdBy=32881678798, createdName=小M医师, createdTime=Thu Jul 07 15:13:00 CST 2016, time=2016-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519698, encodeId=ab9751969855, content=好像挺快的Atlantis 2016-02-10 发表:: 研究方向：淋巴瘤;; 接收率：约75% case report 2015.12.23投稿 2015.12.30改格式 2016.2.8接收, beContent=Atlantis 2016-02-10 发表:: 研究方向：淋巴瘤;; 接收率：约75% case report 2015.12.23投稿 2015.12.30改格式 2016.2.8接收, objectType=tool_impact_factor, channel=null, level=null, likeNumber=465, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=078f1661649, createdName=wei834766788, createdTime=Mon Feb 29 10:02:00 CST 2016, time=2016-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519643, encodeId=b94851964356, content=正常12112312312313 2016-02-02 发表:: 会的, beContent=12112312312313 2016-02-02 发表:: 会的, objectType=tool_impact_factor, channel=null, level=null, likeNumber=359, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=078f1661649, createdName=wei834766788, createdTime=Fri Feb 26 23:03:00 CST 2016, time=2016-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519645, encodeId=1929519645f8, content=看情况的吧zpfsjtu 2016-02-01 发表:: 研究方向：肝癌;泛素化; 这个杂志都是什么状态呀。昨天投稿，今天就under review。应该不会这么快吧。, beContent=zpfsjtu 2016-02-01 发表:: 研究方向：肝癌;泛素化; 这个杂志都是什么状态呀。昨天投稿，今天就under review。应该不会这么快吧。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=469, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=078f1661649, createdName=wei834766788, createdTime=Fri Feb 26 23:02:00 CST 2016, time=2016-02-26, status=1, ipAttribution=)]

2016-09-26 青龙偃月

耐心等结果吧slientwo 2016-09-25 发表::
接收率：约25% 审稿时间：约1个月 Meta分析，在投，under review，5天。会不会不送外审就被拒！

slientwo 2016-09-25 发表:: 接收率：约25% 审稿时间：约1个月 Meta分析，在投，under review，5天。会不会不送外审就被拒！

433 0

[GetPortalCommentsPageByObjectIdResponse(id=527759, encodeId=6c2552e75953, content=被拒！编辑部，给了一个意见。一个月一篇类似文章和你类似！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=516, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Thu Sep 29 20:58:00 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=527733, encodeId=892752e73314, content=Under review 8天，现在decision in process, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=339, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Thu Sep 29 00:07:00 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=527692, encodeId=c13552e69216, content=也只能这样了，万一给拒了，希望给点意见。青龙偃月 2016-09-26 发表:: 耐心等结果吧, beContent=青龙偃月 2016-09-26 发表:: 耐心等结果吧, objectType=tool_impact_factor, channel=null, level=null, likeNumber=333, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Wed Sep 28 00:53:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=527636, encodeId=d8be52e63687, content=耐心等结果吧slientwo 2016-09-25 发表:: 接收率：约25% 审稿时间：约1个月 Meta分析，在投，under review，5天。会不会不送外审就被拒！, beContent=slientwo 2016-09-25 发表:: 接收率：约25% 审稿时间：约1个月 Meta分析，在投，under review，5天。会不会不送外审就被拒！, objectType=tool_impact_factor, channel=null, level=null, likeNumber=433, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160905/IMG57CD39B82D12E7926.jpg, createdBy=ac2c1946830, createdName=青龙偃月, createdTime=Mon Sep 26 22:09:00 CST 2016, time=2016-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=527588, encodeId=3ad452e588ca, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：Meta分析，在投，under review，5天。会不会不送外审就被拒！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=312, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Sep 25 17:21:00 CST 2016, time=2016-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=833102, encodeId=1df48331029e, content=老牌经典期刊，难度较大 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6e05414152, createdName=ms2614478266438915, createdTime=Wed Aug 17 13:31:54 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=524581, encodeId=fa9e52458108, content=是的rolly11 2016-02-29 发表:: 好像挺快的, beContent=rolly11 2016-02-29 发表:: 好像挺快的, objectType=tool_impact_factor, channel=null, level=null, likeNumber=377, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/25/ba882cb566d3be250a05e2a69b80f2c9.jpg, createdBy=32881678798, createdName=小M医师, createdTime=Thu Jul 07 15:13:00 CST 2016, time=2016-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519698, encodeId=ab9751969855, content=好像挺快的Atlantis 2016-02-10 发表:: 研究方向：淋巴瘤;; 接收率：约75% case report 2015.12.23投稿 2015.12.30改格式 2016.2.8接收, beContent=Atlantis 2016-02-10 发表:: 研究方向：淋巴瘤;; 接收率：约75% case report 2015.12.23投稿 2015.12.30改格式 2016.2.8接收, objectType=tool_impact_factor, channel=null, level=null, likeNumber=465, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=078f1661649, createdName=wei834766788, createdTime=Mon Feb 29 10:02:00 CST 2016, time=2016-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519643, encodeId=b94851964356, content=正常12112312312313 2016-02-02 发表:: 会的, beContent=12112312312313 2016-02-02 发表:: 会的, objectType=tool_impact_factor, channel=null, level=null, likeNumber=359, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=078f1661649, createdName=wei834766788, createdTime=Fri Feb 26 23:03:00 CST 2016, time=2016-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519645, encodeId=1929519645f8, content=看情况的吧zpfsjtu 2016-02-01 发表:: 研究方向：肝癌;泛素化; 这个杂志都是什么状态呀。昨天投稿，今天就under review。应该不会这么快吧。, beContent=zpfsjtu 2016-02-01 发表:: 研究方向：肝癌;泛素化; 这个杂志都是什么状态呀。昨天投稿，今天就under review。应该不会这么快吧。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=469, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=078f1661649, createdName=wei834766788, createdTime=Fri Feb 26 23:02:00 CST 2016, time=2016-02-26, status=1, ipAttribution=)]

2016-09-25 slientwo

审稿速度:1.0 | 投稿命中率:25.0
经验分享：Meta分析，在投，under review，5天。会不会不送外审就被拒！

312 0

[GetPortalCommentsPageByObjectIdResponse(id=527759, encodeId=6c2552e75953, content=被拒！编辑部，给了一个意见。一个月一篇类似文章和你类似！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=516, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Thu Sep 29 20:58:00 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=527733, encodeId=892752e73314, content=Under review 8天，现在decision in process, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=339, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Thu Sep 29 00:07:00 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=527692, encodeId=c13552e69216, content=也只能这样了，万一给拒了，希望给点意见。青龙偃月 2016-09-26 发表:: 耐心等结果吧, beContent=青龙偃月 2016-09-26 发表:: 耐心等结果吧, objectType=tool_impact_factor, channel=null, level=null, likeNumber=333, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Wed Sep 28 00:53:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=527636, encodeId=d8be52e63687, content=耐心等结果吧slientwo 2016-09-25 发表:: 接收率：约25% 审稿时间：约1个月 Meta分析，在投，under review，5天。会不会不送外审就被拒！, beContent=slientwo 2016-09-25 发表:: 接收率：约25% 审稿时间：约1个月 Meta分析，在投，under review，5天。会不会不送外审就被拒！, objectType=tool_impact_factor, channel=null, level=null, likeNumber=433, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160905/IMG57CD39B82D12E7926.jpg, createdBy=ac2c1946830, createdName=青龙偃月, createdTime=Mon Sep 26 22:09:00 CST 2016, time=2016-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=527588, encodeId=3ad452e588ca, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：Meta分析，在投，under review，5天。会不会不送外审就被拒！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=312, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Sep 25 17:21:00 CST 2016, time=2016-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=833102, encodeId=1df48331029e, content=老牌经典期刊，难度较大 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6e05414152, createdName=ms2614478266438915, createdTime=Wed Aug 17 13:31:54 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=524581, encodeId=fa9e52458108, content=是的rolly11 2016-02-29 发表:: 好像挺快的, beContent=rolly11 2016-02-29 发表:: 好像挺快的, objectType=tool_impact_factor, channel=null, level=null, likeNumber=377, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/25/ba882cb566d3be250a05e2a69b80f2c9.jpg, createdBy=32881678798, createdName=小M医师, createdTime=Thu Jul 07 15:13:00 CST 2016, time=2016-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519698, encodeId=ab9751969855, content=好像挺快的Atlantis 2016-02-10 发表:: 研究方向：淋巴瘤;; 接收率：约75% case report 2015.12.23投稿 2015.12.30改格式 2016.2.8接收, beContent=Atlantis 2016-02-10 发表:: 研究方向：淋巴瘤;; 接收率：约75% case report 2015.12.23投稿 2015.12.30改格式 2016.2.8接收, objectType=tool_impact_factor, channel=null, level=null, likeNumber=465, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=078f1661649, createdName=wei834766788, createdTime=Mon Feb 29 10:02:00 CST 2016, time=2016-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519643, encodeId=b94851964356, content=正常12112312312313 2016-02-02 发表:: 会的, beContent=12112312312313 2016-02-02 发表:: 会的, objectType=tool_impact_factor, channel=null, level=null, likeNumber=359, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=078f1661649, createdName=wei834766788, createdTime=Fri Feb 26 23:03:00 CST 2016, time=2016-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519645, encodeId=1929519645f8, content=看情况的吧zpfsjtu 2016-02-01 发表:: 研究方向：肝癌;泛素化; 这个杂志都是什么状态呀。昨天投稿，今天就under review。应该不会这么快吧。, beContent=zpfsjtu 2016-02-01 发表:: 研究方向：肝癌;泛素化; 这个杂志都是什么状态呀。昨天投稿，今天就under review。应该不会这么快吧。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=469, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=078f1661649, createdName=wei834766788, createdTime=Fri Feb 26 23:02:00 CST 2016, time=2016-02-26, status=1, ipAttribution=)]

2016-08-17 ms2614478266438915

老牌经典期刊，难度较大

23 0

[GetPortalCommentsPageByObjectIdResponse(id=527759, encodeId=6c2552e75953, content=被拒！编辑部，给了一个意见。一个月一篇类似文章和你类似！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=516, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Thu Sep 29 20:58:00 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=527733, encodeId=892752e73314, content=Under review 8天，现在decision in process, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=339, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Thu Sep 29 00:07:00 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=527692, encodeId=c13552e69216, content=也只能这样了，万一给拒了，希望给点意见。青龙偃月 2016-09-26 发表:: 耐心等结果吧, beContent=青龙偃月 2016-09-26 发表:: 耐心等结果吧, objectType=tool_impact_factor, channel=null, level=null, likeNumber=333, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Wed Sep 28 00:53:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=527636, encodeId=d8be52e63687, content=耐心等结果吧slientwo 2016-09-25 发表:: 接收率：约25% 审稿时间：约1个月 Meta分析，在投，under review，5天。会不会不送外审就被拒！, beContent=slientwo 2016-09-25 发表:: 接收率：约25% 审稿时间：约1个月 Meta分析，在投，under review，5天。会不会不送外审就被拒！, objectType=tool_impact_factor, channel=null, level=null, likeNumber=433, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160905/IMG57CD39B82D12E7926.jpg, createdBy=ac2c1946830, createdName=青龙偃月, createdTime=Mon Sep 26 22:09:00 CST 2016, time=2016-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=527588, encodeId=3ad452e588ca, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：Meta分析，在投，under review，5天。会不会不送外审就被拒！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=312, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Sep 25 17:21:00 CST 2016, time=2016-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=833102, encodeId=1df48331029e, content=老牌经典期刊，难度较大 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6e05414152, createdName=ms2614478266438915, createdTime=Wed Aug 17 13:31:54 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=524581, encodeId=fa9e52458108, content=是的rolly11 2016-02-29 发表:: 好像挺快的, beContent=rolly11 2016-02-29 发表:: 好像挺快的, objectType=tool_impact_factor, channel=null, level=null, likeNumber=377, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/25/ba882cb566d3be250a05e2a69b80f2c9.jpg, createdBy=32881678798, createdName=小M医师, createdTime=Thu Jul 07 15:13:00 CST 2016, time=2016-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519698, encodeId=ab9751969855, content=好像挺快的Atlantis 2016-02-10 发表:: 研究方向：淋巴瘤;; 接收率：约75% case report 2015.12.23投稿 2015.12.30改格式 2016.2.8接收, beContent=Atlantis 2016-02-10 发表:: 研究方向：淋巴瘤;; 接收率：约75% case report 2015.12.23投稿 2015.12.30改格式 2016.2.8接收, objectType=tool_impact_factor, channel=null, level=null, likeNumber=465, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=078f1661649, createdName=wei834766788, createdTime=Mon Feb 29 10:02:00 CST 2016, time=2016-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519643, encodeId=b94851964356, content=正常12112312312313 2016-02-02 发表:: 会的, beContent=12112312312313 2016-02-02 发表:: 会的, objectType=tool_impact_factor, channel=null, level=null, likeNumber=359, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=078f1661649, createdName=wei834766788, createdTime=Fri Feb 26 23:03:00 CST 2016, time=2016-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519645, encodeId=1929519645f8, content=看情况的吧zpfsjtu 2016-02-01 发表:: 研究方向：肝癌;泛素化; 这个杂志都是什么状态呀。昨天投稿，今天就under review。应该不会这么快吧。, beContent=zpfsjtu 2016-02-01 发表:: 研究方向：肝癌;泛素化; 这个杂志都是什么状态呀。昨天投稿，今天就under review。应该不会这么快吧。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=469, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=078f1661649, createdName=wei834766788, createdTime=Fri Feb 26 23:02:00 CST 2016, time=2016-02-26, status=1, ipAttribution=)]

2016-07-07 小M医师

是的rolly11 2016-02-29 发表::
好像挺快的

rolly11 2016-02-29 发表:: 好像挺快的

377 0

[GetPortalCommentsPageByObjectIdResponse(id=527759, encodeId=6c2552e75953, content=被拒！编辑部，给了一个意见。一个月一篇类似文章和你类似！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=516, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Thu Sep 29 20:58:00 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=527733, encodeId=892752e73314, content=Under review 8天，现在decision in process, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=339, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Thu Sep 29 00:07:00 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=527692, encodeId=c13552e69216, content=也只能这样了，万一给拒了，希望给点意见。青龙偃月 2016-09-26 发表:: 耐心等结果吧, beContent=青龙偃月 2016-09-26 发表:: 耐心等结果吧, objectType=tool_impact_factor, channel=null, level=null, likeNumber=333, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Wed Sep 28 00:53:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=527636, encodeId=d8be52e63687, content=耐心等结果吧slientwo 2016-09-25 发表:: 接收率：约25% 审稿时间：约1个月 Meta分析，在投，under review，5天。会不会不送外审就被拒！, beContent=slientwo 2016-09-25 发表:: 接收率：约25% 审稿时间：约1个月 Meta分析，在投，under review，5天。会不会不送外审就被拒！, objectType=tool_impact_factor, channel=null, level=null, likeNumber=433, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160905/IMG57CD39B82D12E7926.jpg, createdBy=ac2c1946830, createdName=青龙偃月, createdTime=Mon Sep 26 22:09:00 CST 2016, time=2016-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=527588, encodeId=3ad452e588ca, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：Meta分析，在投，under review，5天。会不会不送外审就被拒！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=312, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Sep 25 17:21:00 CST 2016, time=2016-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=833102, encodeId=1df48331029e, content=老牌经典期刊，难度较大 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6e05414152, createdName=ms2614478266438915, createdTime=Wed Aug 17 13:31:54 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=524581, encodeId=fa9e52458108, content=是的rolly11 2016-02-29 发表:: 好像挺快的, beContent=rolly11 2016-02-29 发表:: 好像挺快的, objectType=tool_impact_factor, channel=null, level=null, likeNumber=377, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/25/ba882cb566d3be250a05e2a69b80f2c9.jpg, createdBy=32881678798, createdName=小M医师, createdTime=Thu Jul 07 15:13:00 CST 2016, time=2016-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519698, encodeId=ab9751969855, content=好像挺快的Atlantis 2016-02-10 发表:: 研究方向：淋巴瘤;; 接收率：约75% case report 2015.12.23投稿 2015.12.30改格式 2016.2.8接收, beContent=Atlantis 2016-02-10 发表:: 研究方向：淋巴瘤;; 接收率：约75% case report 2015.12.23投稿 2015.12.30改格式 2016.2.8接收, objectType=tool_impact_factor, channel=null, level=null, likeNumber=465, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=078f1661649, createdName=wei834766788, createdTime=Mon Feb 29 10:02:00 CST 2016, time=2016-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519643, encodeId=b94851964356, content=正常12112312312313 2016-02-02 发表:: 会的, beContent=12112312312313 2016-02-02 发表:: 会的, objectType=tool_impact_factor, channel=null, level=null, likeNumber=359, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=078f1661649, createdName=wei834766788, createdTime=Fri Feb 26 23:03:00 CST 2016, time=2016-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519645, encodeId=1929519645f8, content=看情况的吧zpfsjtu 2016-02-01 发表:: 研究方向：肝癌;泛素化; 这个杂志都是什么状态呀。昨天投稿，今天就under review。应该不会这么快吧。, beContent=zpfsjtu 2016-02-01 发表:: 研究方向：肝癌;泛素化; 这个杂志都是什么状态呀。昨天投稿，今天就under review。应该不会这么快吧。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=469, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=078f1661649, createdName=wei834766788, createdTime=Fri Feb 26 23:02:00 CST 2016, time=2016-02-26, status=1, ipAttribution=)]

2016-02-29 wei834766788

好像挺快的Atlantis 2016-02-10 发表::
研究方向：淋巴瘤;; 接收率：约75% case report 2015.12.23投稿 2015.12.30改格式 2016.2.8接收

Atlantis 2016-02-10 发表:: 研究方向：淋巴瘤;; 接收率：约75% case report 2015.12.23投稿 2015.12.30改格式 2016.2.8接收

465 0

[GetPortalCommentsPageByObjectIdResponse(id=527759, encodeId=6c2552e75953, content=被拒！编辑部，给了一个意见。一个月一篇类似文章和你类似！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=516, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Thu Sep 29 20:58:00 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=527733, encodeId=892752e73314, content=Under review 8天，现在decision in process, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=339, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Thu Sep 29 00:07:00 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=527692, encodeId=c13552e69216, content=也只能这样了，万一给拒了，希望给点意见。青龙偃月 2016-09-26 发表:: 耐心等结果吧, beContent=青龙偃月 2016-09-26 发表:: 耐心等结果吧, objectType=tool_impact_factor, channel=null, level=null, likeNumber=333, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Wed Sep 28 00:53:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=527636, encodeId=d8be52e63687, content=耐心等结果吧slientwo 2016-09-25 发表:: 接收率：约25% 审稿时间：约1个月 Meta分析，在投，under review，5天。会不会不送外审就被拒！, beContent=slientwo 2016-09-25 发表:: 接收率：约25% 审稿时间：约1个月 Meta分析，在投，under review，5天。会不会不送外审就被拒！, objectType=tool_impact_factor, channel=null, level=null, likeNumber=433, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160905/IMG57CD39B82D12E7926.jpg, createdBy=ac2c1946830, createdName=青龙偃月, createdTime=Mon Sep 26 22:09:00 CST 2016, time=2016-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=527588, encodeId=3ad452e588ca, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：Meta分析，在投，under review，5天。会不会不送外审就被拒！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=312, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Sep 25 17:21:00 CST 2016, time=2016-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=833102, encodeId=1df48331029e, content=老牌经典期刊，难度较大 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6e05414152, createdName=ms2614478266438915, createdTime=Wed Aug 17 13:31:54 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=524581, encodeId=fa9e52458108, content=是的rolly11 2016-02-29 发表:: 好像挺快的, beContent=rolly11 2016-02-29 发表:: 好像挺快的, objectType=tool_impact_factor, channel=null, level=null, likeNumber=377, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/25/ba882cb566d3be250a05e2a69b80f2c9.jpg, createdBy=32881678798, createdName=小M医师, createdTime=Thu Jul 07 15:13:00 CST 2016, time=2016-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519698, encodeId=ab9751969855, content=好像挺快的Atlantis 2016-02-10 发表:: 研究方向：淋巴瘤;; 接收率：约75% case report 2015.12.23投稿 2015.12.30改格式 2016.2.8接收, beContent=Atlantis 2016-02-10 发表:: 研究方向：淋巴瘤;; 接收率：约75% case report 2015.12.23投稿 2015.12.30改格式 2016.2.8接收, objectType=tool_impact_factor, channel=null, level=null, likeNumber=465, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=078f1661649, createdName=wei834766788, createdTime=Mon Feb 29 10:02:00 CST 2016, time=2016-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519643, encodeId=b94851964356, content=正常12112312312313 2016-02-02 发表:: 会的, beContent=12112312312313 2016-02-02 发表:: 会的, objectType=tool_impact_factor, channel=null, level=null, likeNumber=359, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=078f1661649, createdName=wei834766788, createdTime=Fri Feb 26 23:03:00 CST 2016, time=2016-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519645, encodeId=1929519645f8, content=看情况的吧zpfsjtu 2016-02-01 发表:: 研究方向：肝癌;泛素化; 这个杂志都是什么状态呀。昨天投稿，今天就under review。应该不会这么快吧。, beContent=zpfsjtu 2016-02-01 发表:: 研究方向：肝癌;泛素化; 这个杂志都是什么状态呀。昨天投稿，今天就under review。应该不会这么快吧。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=469, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=078f1661649, createdName=wei834766788, createdTime=Fri Feb 26 23:02:00 CST 2016, time=2016-02-26, status=1, ipAttribution=)]

2016-02-26 wei834766788

正常12112312312313 2016-02-02 发表::
会的

12112312312313 2016-02-02 发表:: 会的

359 0

[GetPortalCommentsPageByObjectIdResponse(id=527759, encodeId=6c2552e75953, content=被拒！编辑部，给了一个意见。一个月一篇类似文章和你类似！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=516, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Thu Sep 29 20:58:00 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=527733, encodeId=892752e73314, content=Under review 8天，现在decision in process, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=339, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Thu Sep 29 00:07:00 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=527692, encodeId=c13552e69216, content=也只能这样了，万一给拒了，希望给点意见。青龙偃月 2016-09-26 发表:: 耐心等结果吧, beContent=青龙偃月 2016-09-26 发表:: 耐心等结果吧, objectType=tool_impact_factor, channel=null, level=null, likeNumber=333, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Wed Sep 28 00:53:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=527636, encodeId=d8be52e63687, content=耐心等结果吧slientwo 2016-09-25 发表:: 接收率：约25% 审稿时间：约1个月 Meta分析，在投，under review，5天。会不会不送外审就被拒！, beContent=slientwo 2016-09-25 发表:: 接收率：约25% 审稿时间：约1个月 Meta分析，在投，under review，5天。会不会不送外审就被拒！, objectType=tool_impact_factor, channel=null, level=null, likeNumber=433, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160905/IMG57CD39B82D12E7926.jpg, createdBy=ac2c1946830, createdName=青龙偃月, createdTime=Mon Sep 26 22:09:00 CST 2016, time=2016-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=527588, encodeId=3ad452e588ca, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：Meta分析，在投，under review，5天。会不会不送外审就被拒！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=312, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sun Sep 25 17:21:00 CST 2016, time=2016-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=833102, encodeId=1df48331029e, content=老牌经典期刊，难度较大 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6e05414152, createdName=ms2614478266438915, createdTime=Wed Aug 17 13:31:54 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=524581, encodeId=fa9e52458108, content=是的rolly11 2016-02-29 发表:: 好像挺快的, beContent=rolly11 2016-02-29 发表:: 好像挺快的, objectType=tool_impact_factor, channel=null, level=null, likeNumber=377, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/25/ba882cb566d3be250a05e2a69b80f2c9.jpg, createdBy=32881678798, createdName=小M医师, createdTime=Thu Jul 07 15:13:00 CST 2016, time=2016-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519698, encodeId=ab9751969855, content=好像挺快的Atlantis 2016-02-10 发表:: 研究方向：淋巴瘤;; 接收率：约75% case report 2015.12.23投稿 2015.12.30改格式 2016.2.8接收, beContent=Atlantis 2016-02-10 发表:: 研究方向：淋巴瘤;; 接收率：约75% case report 2015.12.23投稿 2015.12.30改格式 2016.2.8接收, objectType=tool_impact_factor, channel=null, level=null, likeNumber=465, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=078f1661649, createdName=wei834766788, createdTime=Mon Feb 29 10:02:00 CST 2016, time=2016-02-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519643, encodeId=b94851964356, content=正常12112312312313 2016-02-02 发表:: 会的, beContent=12112312312313 2016-02-02 发表:: 会的, objectType=tool_impact_factor, channel=null, level=null, likeNumber=359, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=078f1661649, createdName=wei834766788, createdTime=Fri Feb 26 23:03:00 CST 2016, time=2016-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519645, encodeId=1929519645f8, content=看情况的吧zpfsjtu 2016-02-01 发表:: 研究方向：肝癌;泛素化; 这个杂志都是什么状态呀。昨天投稿，今天就under review。应该不会这么快吧。, beContent=zpfsjtu 2016-02-01 发表:: 研究方向：肝癌;泛素化; 这个杂志都是什么状态呀。昨天投稿，今天就under review。应该不会这么快吧。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=469, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=078f1661649, createdName=wei834766788, createdTime=Fri Feb 26 23:02:00 CST 2016, time=2016-02-26, status=1, ipAttribution=)]

2016-02-26 wei834766788

看情况的吧zpfsjtu 2016-02-01 发表::
研究方向：肝癌;泛素化; 这个杂志都是什么状态呀。昨天投稿，今天就under review。应该不会这么快吧。

zpfsjtu 2016-02-01 发表:: 研究方向：肝癌;泛素化; 这个杂志都是什么状态呀。昨天投稿，今天就under review。应该不会这么快吧。

469 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务